Moberg Pharma AB (publ) (MB8.F)
- Previous Close
0.6845 - Open
0.6740 - Bid 0.6860 x --
- Ask 0.7865 x --
- Day's Range
0.6740 - 0.6740 - 52 Week Range
0.5545 - 3.3600 - Volume
40 - Avg. Volume
0 - Market Cap (intraday)
33.113M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
--
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
www.mobergpharma.se9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MB8.F
View MorePerformance Overview: MB8.F
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MB8.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MB8.F
View MoreValuation Measures
Market Cap
34.46M
Enterprise Value
8.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.36
Price/Book (mrq)
0.50
Enterprise Value/Revenue
9.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.28%
Return on Equity (ttm)
-39.32%
Revenue (ttm)
9.81M
Net Income Avi to Common (ttm)
-255.11M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
293.29M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
27.29M